Days af­ter an FDA ap­proval for its pso­ri­a­sis drug, Ar­cutis looks to raise $150M in pub­lic cap­i­tal

In this bear­ish mar­ket, pub­lic com­pa­nies have raced to in­vestors pri­mar­i­ly on­ly af­ter show­ing im­pres­sive clin­i­cal da­ta or reach­ing oth­er promi­nent mile­stones. And as the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER